LUXEMBOURG, February 28, 2013 /PRNewswire/ --
Creabilis SA, a late clinical stage European biotechnology company specialising in the development of treatments in dermatology, inflammation and pain, today announces that it has appointed Catherine Moukheibir to its Board of Directors.
Catherine has gained a wealth of experience in the pharmaceutical industry and finance in career spanning more than 30 years. She is currently Senior Advisor, Finance and Member of the Executive Committee at Innate Pharma, where she was responsible for a key licensing deal between the Company and Bristol-Myers Squibb. Prior to joining Innate Pharma, Catherine was Chief Financial Officer at Movetis, where she played a major role in the Company's IPO on Euronext Brussels and subsequent acquisition by Shire. Prior to joining Movetis, Catherine held a number of senior roles in investment banking including roles at Morgan Stanley and Salomon Smith Barney.
Catherine has held a number of other non-executive positions, including OctoPlus NV and is a partner at STJ Advisors in London. She has an MA and MBA from Yale University, USA.
Catherine Moukheibir, commenting on her appointment, said: "I'm delighted to join the Creabilis board. The company has matured and now enters an important phase in its ambition to bring advanced science to dermatology, in particular through CT327, in the treatment of chronic pruritus. I look forward to working with the experienced Creabilis team to deliver value from CT327 and other products in its pipeline."
Dr Eliot Forster CEO of Creabilis said: "It is a pleasure to welcome Catherine to our Board of Directors. Her international financial background and successful transaction experience will significantly benefit the company as we seek to maximise the value of our lead product, CT327, in the treatment of chronic pruritus. It is a reflection of Creabilis' advancement as a business that we have been able to attract someone of Catherine's calibre to the Board. We look forward to working with her."
About Creabilis SA
Creabilis is a clinical-stage European biotechnology company creating innovative new drugs to tackle unmet medical needs in dermatology, inflammation and pain. Bringing together world class drug development capabilities and a rich scientific heritage, Creabilis is uniquely positioned to transform the treatment of its target diseases.
Creabilis' lead product is CT327, a novel topically applied TrkA kinase inhibitor developed using the Company's Low Systemic Exposure (LSE) technology. CT327 is currently in late stage clinical development for chronic pruritus of dermatological disease. CT340 is a potent kinase inhibitor under development for the treatment of pain.
Creabilis is backed by some of the most highly respected life sciences investors including Sofinnova Partners, Neomed Management and Abbott Biotech Ventures, Inc (now AbbVie Biotech Ventures).
For further information please contact:
15 rue Edward Steichen L-2540 LUXEMBOURG
Citigate Dewe Rogerson
Chris Gardner or Nina Enegren
SOURCE Creabilis SA